Eton Pharma Stock Is Trading Higher After FDA Approval For Rezipres

by Vandana Singh, Benzinga Editor

June 15, 2021 11:54 AM | 27 seconds read

The FDA has approved Eton Pharmaceuticals Inc's ETON Rezipres (ephedrine hydrochloride injection) to treat clinically significant hypotension occurring in the setting of anesthesia.
Rezipres is already available in Europe.
The company currently owns or receives royalties from four FDA-approved products, including Alkindi Sprinkle, Biorphen, Rezipres, and Alaway Preservative Free, and has five additional products that have been submitted to the FDA.
Price Action: ETON shares are up 7.06% at $6.98 during the market session on the last check Tuesday.

Posted In: Biotech News Health Care FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.